News

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the APOLLO-B Phase 3 study of patisiran, an…

Novo Nordisk has struck a $1.2 billion deal to buy Prothena’s ATTR amyloidosis program, which was stalled by the pandemic last year.The deal will see Novo pay $100…

AbstractTransthyretin amyloid cardiomyopathy (ATTR-CM) results in a restrictive cardiomyopathy caused by extracellular deposition of transthyretin, normally…

The American Society of Nuclear Cardiologyexternal link, opens in a new tab designates this live activity for a maximum of 4 CME Credits(tm). Physicians should…

The American Society of Nuclear Cardiology (ASNC)external link, opens in a new tab will again host the annual nuclear cardiology and cardiac CT for fellows in…

This discussion was recorded on March 24, 2020. American Society of Nuclear Cardiology (ASNC) leaders and global leaders in China and Singapore addressed the…

The Amyloidosis Foundationexternal link, opens in a new tab is proud to be a partner at this event, Amyloidosis: A Disease Now at the Forefront of Practice Latest…

Bayer has reported that iodine 124 evuzamitide met both primary endpoints in the Phase III REVEAL study, demonstrating sufficient sensitivity and specificity for…

ardiac amyloidosis is characterized by deposition of misfolded protein in the myocardium causing mainly heart failure symptoms with preserved left ventricular…

On January 29–30, 2026, we had the privilege of bringing together patients, advocates, clinicians, and industry partners in Phoenix, Arizona, for the Updates in…